These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 24687799)

  • 1. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer.
    Neesse A; Michl P; Tuveson DA; Ellenrieder V
    Z Gastroenterol; 2014 Apr; 52(4):360-6. PubMed ID: 24687799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The winning formulation: the development of paclitaxel in pancreatic cancer.
    Ma WW; Hidalgo M
    Clin Cancer Res; 2013 Oct; 19(20):5572-9. PubMed ID: 23918602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions.
    Giordano G; Pancione M; Olivieri N; Parcesepe P; Velocci M; Di Raimo T; Coppola L; Toffoli G; D'Andrea MR
    World J Gastroenterol; 2017 Aug; 23(32):5875-5886. PubMed ID: 28932079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action.
    Al-Batran SE; Geissler M; Seufferlein T; Oettle H
    Oncol Res Treat; 2014; 37(3):128-34. PubMed ID: 24685917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nab-paclitaxel].
    Lopez-Trabada Ataz D; Dumont S; André T
    Bull Cancer; 2015 Jun; 102(6):568-76. PubMed ID: 26008630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
    Hosein PJ; de Lima Lopes G; Pastorini VH; Gomez C; Macintyre J; Zayas G; Reis I; Montero AJ; Merchan JR; Rocha Lima CM
    Am J Clin Oncol; 2013 Apr; 36(2):151-6. PubMed ID: 22307213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. nab-Paclitaxel mechanisms of action and delivery.
    Yardley DA
    J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
    Neesse A; Frese KK; Chan DS; Bapiro TE; Howat WJ; Richards FM; Ellenrieder V; Jodrell DI; Tuveson DA
    Gut; 2014 Jun; 63(6):974-83. PubMed ID: 24067278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
    Megerdichian C; Olimpiadi Y; Hurvitz SA
    Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer.
    Ciruelos E; Jackisch C
    Expert Rev Anticancer Ther; 2014 May; 14(5):511-21. PubMed ID: 24575935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxanes: impact on pancreatic cancer.
    Chiorean EG; Von Hoff DD
    Anticancer Drugs; 2014 May; 25(5):584-92. PubMed ID: 24463484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer.
    De Luca R; Blasi L; Alù M; Gristina V; Cicero G
    Drug Des Devel Ther; 2018; 12():1769-1775. PubMed ID: 29950811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy evaluation of albumin-bound paclitaxel.
    Cecco S; Aliberti M; Baldo P; Giacomin E; Leone R
    Expert Opin Drug Saf; 2014 Apr; 13(4):511-20. PubMed ID: 24559090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
    Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
    Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.
    Cullis J; Siolas D; Avanzi A; Barui S; Maitra A; Bar-Sagi D
    Cancer Immunol Res; 2017 Mar; 5(3):182-190. PubMed ID: 28108630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin-bound paclitaxel: a next-generation taxane.
    Gradishar WJ
    Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma.
    Wagner LM; Yin H; Eaves D; Currier M; Cripe TP
    Pediatr Blood Cancer; 2014 Nov; 61(11):2096-8. PubMed ID: 24753077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing Nab-Paclitaxel Delivery Using Microbubble-Assisted Ultrasound in a Pancreatic Cancer Model.
    Bressand D; Novell A; Girault A; Raoul W; Fromont-Hankard G; Escoffre JM; Lecomte T; Bouakaz A
    Mol Pharm; 2019 Sep; 16(9):3814-3822. PubMed ID: 31356090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.
    Hirsh V
    Expert Rev Anticancer Ther; 2014 Feb; 14(2):129-41. PubMed ID: 24467217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
    Henderson IC; Bhatia V
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.